Re: Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

Journal of the National Cancer Institute

Volumn 104, Issue 14, 2012, Pages 1107-1109

  Kantoff, Philip W ^a   Higano, Celestia S ^b   Small, Eric J ^c   Whitmore, James B ^a   Frohlich, Mark W ^d   Schellhammer, Paul F ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Dendreon   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIPULEUCEL T;

CASTRATION RESISTANT PROSTATE CANCER; HAZARD RATIO; HUMAN; IMMUNOTHERAPY; INFECTION; INTERDISCIPLINARY RESEARCH; LETTER; LEUKAPHERESIS; LYMPHOCYTE; MEDICARE; OVERALL SURVIVAL; PRIORITY JOURNAL;

AGING; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; TISSUE EXTRACTS;

EID: 84864487608     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs279     Document Type: Letter

References (15)

1. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104(4): 273-279.
2. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26(15):2544-2549.
3. Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. Clinical outcomes by age in men with hormone refractory prostate cancer: A pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol. 2006;176(1):81-86.
4. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration- resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
5. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, doubleblind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel- T in advanced prostate cancer. Cancer. 2009;115(16):3670-3679.
6. Fan C, George B, Bross P. FDA Clinical Review: Sipuleucel-T. Silver Spring, MD: FDA; 2010. http://www.fda.gov/downloads/biologicsbloodvaccines/ cellulargenetherapyproducts/approvedproducts/ucm214540.pdf. Accessed January 30, 2012.
7. Scher HI, Jia X, Chi K, et al. Randomized, openlabel phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29(16):2191-2198.
8. Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14(9):2763-2767.
9. Anderson J. Minimal pain hormone refractory prostate cancer: Optimising care [online]. Published November 6, 2008. http://www.peerviewpress.com/ evidence-based-decisionsmanagement- advanced-prostate-cancer-0#. Accessed January 30, 2012.
10. Sprent J, Cho JH, Boyman O, Surh CD. T cell homeostasis. Immunol Cell Biol. 2008;86(4):312-319.
11. Osgood EE. Number and distribution of human hemic cells. Blood. 1954;9(12):1141-1154.
12. Di Mascio M, Paik CH, Carrasquillo JA, et al. Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood. 2009;114(2):328-337.
13. Trepel F. Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr. 1974;52(11):511-515.
14. Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apher. 1994;9(2):130-134.
15. Hall SJ, Klotz L, Pantuck AJ, et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011;186(3):877-881.